Search

Your search keyword '"BOGUNIEWICZ, Mark"' showing total 875 results
Start Over Author "BOGUNIEWICZ, Mark"
875 results on '"BOGUNIEWICZ, Mark"'

204. Cost of atopic dermatitis and eczema in the United States

Author

Ellis, Charles N., Drake, Lynn A., Prendergast, Mary M., Abramovits, William, Boguniewicz, Mark, Daniel, Ralph C., Lebwohl, Mark, Stevens, Seth R., Whitaker-Worth, Diane L., Cheng, Wang J., and Tong, Kuo B.

Published
2002

213. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

Author

Eckert, Laurent, primary, Gadkari, Abhijit, additional, Mallya, Usha G., additional, Yang, Min, additional, Nelson, Lauren, additional, Brown, Michelle, additional, Reaney, Matt, additional, Mahajan, Puneet, additional, Guillemin, Isabelle, additional, Simpson, Eric, additional, Boguniewicz, Mark, additional, and Pariser, David, additional

Published
2019
Full Text
View/download PDF

214. Nonlesional Atopic Dermatitis Skin Shows Alterations in Langerhans Cells in Close Proximity to Tight Junction Fragmentation

Author

Yoshida, Takeshi, primary, Cahill, Mike P., additional, Fung, Angus R., additional, Simpson, Eric L., additional, Boguniewicz, Mark, additional, Hanifin, Jon M., additional, De Benedetto, Anna, additional, David, Gloria L., additional, Schlievert, Patrick M., additional, Leung, Donald Y.M., additional, and Beck, Lisa A., additional

Published
2019
Full Text
View/download PDF

216. Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)

Author

Boguniewicz, Mark, primary, Thaçi, Diamant, additional, Lio, Peter A., additional, Hultsch, Thomas, additional, Rossi, Ana B., additional, Eckert, Laurent, additional, Gadkari, Abhijit, additional, Shumel, Brad, additional, Chen, Qiuyue, additional, Chen, Zhen, additional, and Ardeleanu, Marius, additional

Published
2019
Full Text
View/download PDF

232. Contributors

Author

Abzug, Mark J., Akdis, Cezmi A., Akin, Cem, Allen, Katrina, Arzt-Gradwohl, Lisa, Bacharier, Leonard B., Ballow, Mark, Banta, Erin, Beauregard, Alexia, Bender, Bruce G., Berin, M. Cecilia, Bielory, Brett P., Bielory, Leonard, Boguniewicz, Mark, Bush, Andrew, Chan, Kenny H., Chang, Anne B., Chehade, Mirna, Chiriac, Anca M., Cicutto, Lisa, Covar, Ronina A., Cunningham-Rundles, Charlotte, Demoly, Pascal, Eiwegger, Thomas, Fleming, Louise, Fonacier, Luz, Furuta, Glenn T., Gleason, Melanie, Grant, Torie, Groetch, Marion, Guilbert, Theresa W., Gupta, Malika, Hamilton, Robert G., Holland, Steven M., Holloway, John W., Jackson, Daniel J., Joshi, Shyam R., Kattan, Meyer, Khan, David A., Kohn, Donald B., Koplin, Jennifer, Kovalszki, Anna, Lau, Susanne G., Leung, Donald Y.M., Liacouras, Chris A., Liu, Andrew H., Lozano-Ojalvo, Daniel, Maglione, Paul J., Marchant, Julie M., Markowitz, Jonathan E., Martinez, Fernando D., McDowell, Karen M., Matsui, Elizabeth C., Muir, Amanda B., Notarangelo, Luigi D., Nowak-Węgrzyn, Anna, Oliveira, Joao Bosco, Oude Elberink, Hanneke (Joanne) N.G., Palomares, Oscar, Perez, Elena E., Phipatanakul, Wanda, Rosenzweig, Sergio D., Sampson, Hugh A., Scurlock, Amy M., Sheehan, William J., Shreffler, Wayne G., Sicherer, Scott H., Soyka, Michael B., Spahn, Joseph D., Stokes, Jeffrey R., Sturm, Gunter J., Sullivan, Kathleen E., Szefler, Stanley J., Torgerson, Troy R., Varshney, Pooja, Venter, Carina, von Mutius, Erika, Wang, Julie, Weber, Richard W., and Wood, Robert A.

Published
2021
Full Text
View/download PDF

233. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

Author

Leung, Donald Y.M., Kelly, Ciaran P., Boguniewicz, Mark, Pothoulakis, Charalabos, LaMont, J. Thomas, and Flores, Alejandro

Subjects
Gamma globulins -- Evaluation, Gamma globulins -- Health aspects, Colitis -- Care and treatment, Colitis -- Causes of, Health
Abstract

A study was carried out of six children with chronic relapsing colitis (inflammation of the large bowel) due to Clostridium difficile, an infectious organism. The children had undergone antibiotic treatment before the study began. Chronic relapsing colitis may result, in some cases, from patients' abnormally low levels of antibodies against toxin A, one of two toxins produced by Clostridium difficile. To learn more about this possibility, blood tests were carried out on the six patients, 24 healthy children, and 18 healthy adults. Results showed that patients' levels of IgG antibodies (a type of antibody) against toxin A were lower than the levels in control children or adults. Five children were treated with intravenously administered gamma globulin (IVGG, an infusion containing antibodies); during this time, no antibiotics were given. This led to a reduction in the frequency of bowel movements and to the elimination of symptoms of colitis in four patients even after IVGG therapy stopped. It is likely that colitis caused by toxins released by Clostridium difficile developed in these patients as a complication of antibiotic treatment of upper respiratory tract infections. IVGG therapy appears effective for treating chronic relapsing colitis due to Clostridium difficile, particularly in patients who have low levels of IgG antibodies against toxin A. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

234. Atopic Dermatitis (eczema) Guidelines 2023: Highlights

Author

De Benedetto, Anna, Boguniewicz, Mark, Ong, Peck Y., Chu, Derek K., and Schneider, Lynda C.

Abstract

Atopic Dermatitis (AD) is one of the most common chronic inflammatory skin disorders with a complex pathogenesis. AD is characterized by eczematous skin lesions, pruritus, and recurrent skin infections; with negative impact on patients (and caregivers) quality of life.

Published
2024
Full Text
View/download PDF

235. Current and Emerging Biologics for Atopic Dermatitis

Author

Nevid, Michael and Boguniewicz, Mark

Abstract

Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.

Published
2024
Full Text
View/download PDF

236. Use of Vaccines in Patients Receiving Dupilumab, A Systematic Review and Expert Delphi Consensus Recommendation: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A, Chu, Derek K, Ahmed, Tasnuva, Dribin, Timothy E, Abrams, Elissa M, Anagnostou, Aikaterini, Blumenthal, Kimberly G, Boguniewicz, Mark, Chase, Nicole M, Golden, David BK, Hartog, Nicholas L, Heimall, Jennifer R, Ho, Tina, Lawrence, Monica G, Khan, David A, Minniear, Timothy Dean, Mustafa, S Shahzad, Oppenheimer, John J, Phillips, Elizabeth J, Ramsey, Allison, Rider, Nicholas L, Schneider, Lynda, Shaker, Marcus S, Spergel, Jonathan M, Stone, Cosby A, Stukus, David R, Wang, Julie, and Greenhawt, Matthew J

Abstract

Dupilumab is a monoclonal antibody targeting the interleukin (IL)-4 receptor alpha subunit, thus blocking the effects of IL-4 and IL-13, and has shown efficacy in treating various conditions including asthma, atopic dermatitis, eosinophilic esophagitis, and others. Due to its immune modulatory effects, clinical trials studying dupilumab did not allow for patients to receive live vaccines during the clinical trials out of an abundance of caution, and thus package insert recommends patients being treated with dupilumab avoid live vaccines. As dupilumab is now approved down to 6 months of age for the treatment of atopic dermatitis, this reported contraindication is now posing a clinical dilemma for patients and clinicians.

Published
2024
Full Text
View/download PDF

237. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels

Author

Boguniewicz, Mark, Jaffe, Howard S., Izu, Allen, Sullivan, Mary Jean, York, David, Geha, Raif S., and Leung, Donald Y. M.

Subjects
Immunoglobulin E -- Measurement, Atopic dermatitis -- Drug therapy, Interferon gamma -- Evaluation, Atopic dermatitis -- Care and treatment, Health, Health care industry
Abstract

PURPOSE: ReCombinant gamma interferon (rIFN(gamma)) inhibits IgE synthesis in 4tro bY human Peripheral blood mononuclear cells (PBMC). These data suggest a role for rIFN-(gamma) in the treatment of patients with severe atopic dermatitis (AD) and elevated IgE levels. The purpose of this study was to determine the effect of rIFN-(gamma) treatment on IgE production in patients with AD. PATIENTS AND METHODS: Twenty-two patients with chronic severe AD were treated with rIFN-(gamma). In part I of the study, 14 patients were treated with daily subcutaneous injections at three successive dose levels (0.01 mg/M(sup 2)0.05 mg/M(sup 2, and 0.1 Mg/M (sup 2) for 5 days with 2 days off between each dose level. In part II, eight patients received rIFN-(gamma) at 0.05 Mg/M(sup 2), daily for 6 weeks. One patient from part I and eight patients from part Il of the study received three times per week maintenance therapy for up to 14 months. Prior to and at selected times during and after treatment, the clinical and immunologic status of the patients was assessed. RESULTS. In part 1, spontaneous de novo IgE synthesis by PBMC was inhibited in 10 patients receiving rIFN--(gamma) at 0.01 mg/M(sup 2) (p = 0.038) and in nine at 0.1 Mg/M(sup 2) (p = 0.066). There was no reduction of serum IgE levels at any of the three dose levels. Total clinical severity showed improvement at each dose level p, Atopic dermatitis (AD) is a skin inflammation, accompanied by severe itchiness. Hospitalization may be required to control chronic AD, and treatment is directed toward control of symptoms. The cause of AD is not known, but it has been suggested that elevated levels of immunoglobulin E (IgE) may contribute to the condition. It has been reported that interferon gamma may suppress the synthesis of IgE. Laboratory experiments have suggested that this suppression is carried out by human peripheral blood mononuclear cells (PBMC). This study was designed to determine the effect of gamma interferon on IgE production in AD patients. Twenty-two patients with AD were treated with gamma interferon; 14 patients were treated with daily injections of various doses of IgE. There were no reductions in IgE levels at any dose level. However, clinical improvement increased with dose, and the condition worsened when therapy was discontinued. In part two of the study, eight patients were given gamma interferon daily for six weeks. These patients showed no decrease in IgE synthesis by PBMC, or in serum IgE levels. There was significant reduction in clinical disease severity, and this improvement continued during maintenance therapy. It is concluded that treatment with IgE may be effective in treating AD, and further research is warranted. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

238. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.

Author

Paller, Amy S., Bansal, Ashish, Simpson, Eric L., Boguniewicz, Mark, Blauvelt, Andrew, Siegfried, Elaine C., Guttman-Yassky, Emma, Hultsch, Thomas, Chen, Zhen, Mina-Osorio, Paola, Lu, Yufang, Rossi, Ana B., He, Xinyi, Kamal, Mohamed, Graham, Neil M. H., Pirozzi, Gianluca, Ruddy, Marcella, Eckert, Laurent, and Gadkari, Abhijit

Subjects
DUPILUMAB, THERAPEUTIC use of monoclonal antibodies, ATOPIC dermatitis, CONFIDENCE intervals, MONOCLONAL antibodies, HEALTH outcome assessment, PLACEBOS, QUALITY of life, QUESTIONNAIRES, STATISTICAL sampling, STATISTICS, TIME, DATA analysis, RANDOMIZED controlled trials, TREATMENT effectiveness, DESCRIPTIVE statistics, ADOLESCENCE
Abstract

Background: Atopic dermatitis is a chronic inflammatory condition with substantial burden and limited treatment options for adolescents with moderate-to-severe disease. Significantly more patients treated with dupilumab vs. placebo achieved Investigator's Global Assessment 0/1 at week 16. Objective: The objective of this study was to assess the impact of dupilumab treatment vs. placebo on the achievement of clinically meaningful improvements in atopic dermatitis signs, symptoms and quality of life. Methods: R668-AD-1526 LIBERTY AD ADOL was a randomized, double-blinded, parallel-group, phase III clinical trial. Two hundred and fifty-one adolescents with moderate-to-severe atopic dermatitis received dupilumab 300 mg every 4 weeks (q4w; n = 84), dupilumab 200 or 300 mg every 2 weeks (q2w; n = 82), or placebo (n = 85). A post-hoc subgroup analysis was performed on 214 patients with Investigator's Global Assessment > 1 at week 16. Measures of atopic dermatitis signs, symptoms, and quality of life were assessed. Clinically meaningful improvement in one or more of three domains of signs, symptoms, and quality of life was defined as an improvement of ≥ 50% in Eczema Area and Severity Index, ≥ 3 points in Peak Pruritus Numerical Rating Scale, or ≥ 6 points in the Children's Dermatology Life Quality Index from baseline. Results: Of patients receiving dupilumab q2w, 80.5% [66/82] experienced clinically meaningful improvements in atopic dermatitis signs, symptoms, or quality of life at week 16 (vs. placebo, 20/85 [23.5%], difference 57.0% [95% confidence interval 44.5–69.4]; q4w vs. placebo, 53/84 [63.1%], difference 39.6% [95% confidence interval 25.9–53.3]; both p < 0.0001). Results were similar in adolescents with Investigator's Global Assessment > 1 at week 16 (q2w, 46/62 [74.2%] vs. placebo, 18/83 [21.7%], difference 52.5% [95% confidence interval 38.5–66.6]; q4w, 38/69 [55.1%] vs. placebo, difference 33.4% [95% confidence interval 18.7–48.1]; both p < 0.0001). Conclusions: Dupilumab provided clinically meaningful improvements in signs, symptoms, and quality of life in adolescents with moderate-to-severe atopic dermatitis among patients with Investigator's Global Assessment > 1 at week 16. Treatment responses should be interpreted in the context of such clinically relevant patient-reported outcome measures. Trial Registration: ClinicalTrials.gov; NCT03054428. Adolescents with atopic dermatitis: does dupilumab improve their signs, symptoms, and quality of life? (MP4 212916 kb) [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

244. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders

Author

Paller, Amy, primary, Jaworski, Jennifer C., additional, Simpson, Eric L., additional, Boguniewicz, Mark, additional, Russell, John J., additional, Block, Julie K., additional, Tofte, Susan, additional, Dunn, Jeffrey D., additional, Feldman, Steven R., additional, Clark, Adele R., additional, Schwartz, Gene, additional, and Eichenfield, Lawrence F., additional

Published
2018
Full Text
View/download PDF

245. Crisaborole Ointment Effect on Global Atopic Dermatitis Severity and Early Relief in Pruritus: Pooled Results From Two Phase 3 Clinical Trials

Author

Paller, Amy S., primary, Yosipovitch, Gil, additional, Tom, Wynnis L., additional, Lebwohl, Mark, additional, Boguniewicz, Mark, additional, Call, Robert S., additional, Eichenfield, Lawrence F., additional, Forsha, Douglass W., additional, Rees, William C., additional, Simpson, Eric L., additional, Stein Gold, Linda F., additional, Zaenglein, Andrea L., additional, Tallman, Anna M., additional, Tan, Bill, additional, and Hebert, Adelaide A., additional

Published
2018
Full Text
View/download PDF

246. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry

Author

Siegfried, Elaine C., primary, Jaworski, Jennifer C., additional, Eichenfield, Lawrence F., additional, Paller, Amy, additional, Hebert, Adelaide A., additional, Simpson, Eric L., additional, Altman, Emily, additional, Arena, Charles, additional, Blauvelt, Andrew, additional, Block, Julie, additional, Boguniewicz, Mark, additional, Chen, Suephy, additional, Cordoro, Kelly, additional, Hanna, Diane, additional, Horii, Kimberly, additional, Hultsch, Thomas, additional, Lee, James, additional, Leung, Donald Y., additional, Lio, Peter, additional, Milner, Joshua, additional, Omachi, Theodore, additional, Schneider, Christine, additional, Schneider, Lynda, additional, Sidbury, Robert, additional, Smith, Timothy, additional, Sugarman, Jeffrey, additional, Taha, Sharif, additional, Tofte, Susan, additional, Tollefson, Megha, additional, Tom, Wynnis L., additional, West, Dennis P., additional, Whitney, Lucinda, additional, and Zane, Lee, additional

Published
2018
Full Text
View/download PDF

247. Patients with adult- and late childhood-onset atopic dermatitis report a higher burden of disease severity than patients with early childhood-onset atopic dermatitis.

Author

Ong, Peck Y., primary, Fuxench, Zelma Chiesa, additional, Fonacier, Luz S., additional, Schwartz, Lawrence B., additional, Grayson, Mitchell H., additional, Block, Julie, additional, Mitchell, Lynda, additional, Gelfand, Joel M., additional, Silverberg, Jonathan I., additional, Margolis, David J., additional, Boguniewicz, Mark, additional, and Simpson, Eric L., additional

Published
2018
Full Text
View/download PDF

248. Staphylococcus Aureus -Culture Positivity Observed In Adults With Atopic Dermatitis Is Most Indicative Of An Increased Absolute and Relative Abundance Of S. Aureus and Not Reduced Biodiversity

Author

Yoshida, Takeshi, primary, Grier, Alex, additional, Gill, Ann, additional, Corbett, Anthony, additional, Cahill, Mike P., additional, Lockhart, Alexandre, additional, Simpson, Eric L., additional, Boguniewicz, Mark, additional, Hanifin, Jon M., additional, De Benedetto, Anna, additional, David, Gloria L., additional, Leung, Donald Y.M., additional, Schlievert, Patrick M., additional, Gill, Steven R., additional, and Beck, Lisa A., additional

Published
2018
Full Text
View/download PDF

250. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

Author

Boguniewicz, Mark, primary, Alexis, Andrew F., additional, Beck, Lisa A., additional, Block, Julie, additional, Eichenfield, Lawrence F., additional, Fonacier, Luz, additional, Guttman-Yassky, Emma, additional, Paller, Amy S., additional, Pariser, David, additional, Silverberg, Jonathan I., additional, and Lebwohl, Mark, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results